FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:1925-1926 December 16, 1999 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Staszewski, S. Related Article by Starr, S. E. PubMed Citation

Fifteen drugs are currently available for the treatment of patients with human immunodeficiency virus type 1 (HIV-1) infection, all of which target the virally encoded transcriptase or protease enzymes. Under development is a second generation of antiretroviral drugs that are more potent or that act at different sites of the viral replicative cycle. Theoretically, many combinations of drugs are possible. However, because of interactions between drugs, additive toxicity, and cross-resistance, the actual number of therapeutic options is limited in previously treated patients; this fact underscores the importance of initiating therapy for HIV-1 infection with the best possible regimen.

After years . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Kraft, W. K., McCrea, J. B., Winchell, G. A., Carides, A., Lowry, R., Woolf, E. J., Kusma, S. E., Deutsch, P. J., Greenberg, H. E., Waldman, S. A. (2004). Indinavir and Rifabutin Drug Interactions in Healthy Volunteers. J Clin Pharmacol 44: 305-313 [Abstract] [Full Text]  
• Chavan, S., Kodoth, S., Pahwa, R., Pahwa, S. (2001). The HIV protease inhibitor Indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals. Blood 98: 383-389 [Abstract] [Full Text]  
• (2000). Antiretroviral Failure: A Biopsychosocial Approach. AIDS Clin Care 2000: 1-1 [Full Text]  
• (2000). Powerful Antiretroviral Therapy Without Protease Inhibitors. JWatch Gastroenterology 2000: 16-16 [Full Text]  
• (2000). Efavirenz vs. Indinavir. AIDS Clin Care 2000: 2-2 [Full Text]  
• (1999). Powerful Antiretroviral Therapy Without Protease Inhibitors. JWatch General 1999: 2-2 [Full Text]